Esreboxetine has been used in trials studying the treatment and basic science of Fibromyalgia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Hydrocodone | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Magnesium sulfate | The therapeutic efficacy of Esreboxetine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Esreboxetine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Mirtazapine | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Orphenadrine | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Pramipexole | Esreboxetine may increase the sedative activities of Pramipexole. |
| Ropinirole | Esreboxetine may increase the sedative activities of Ropinirole. |
| Rotigotine | Esreboxetine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Esreboxetine. |
| Sodium oxybate | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Thalidomide | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Esreboxetine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Esreboxetine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Esreboxetine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Esreboxetine is combined with (S)-Warfarin. |
| Ethanol | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Esreboxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Alaproclate. |
| Iobenguane | Esreboxetine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zopiclone | The risk or severity of adverse effects can be increased when Esreboxetine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Esreboxetine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Esreboxetine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Esreboxetine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Esreboxetine. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Esreboxetine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Esreboxetine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Esreboxetine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Esreboxetine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Esreboxetine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Esreboxetine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Esreboxetine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Esreboxetine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Esreboxetine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Esreboxetine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Esreboxetine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Esreboxetine. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Esreboxetine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Esreboxetine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Esreboxetine. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Esreboxetine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Esreboxetine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Esreboxetine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Esreboxetine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Esreboxetine. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Esreboxetine. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Esreboxetine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Esreboxetine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Esreboxetine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Esreboxetine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Esreboxetine. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Esreboxetine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Esreboxetine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Esreboxetine. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Esreboxetine. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Esreboxetine. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Esreboxetine. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Esreboxetine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Esreboxetine. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Esreboxetine. |